A recent observational study published in Obstetrics & Gynecology confirms a significant association between the maximum oxytocin dose administered during a Trial of Labor After Cesarean (TOLAC) and the risk of uterine rupture. Clinicians must understand this dose-response relationship to ensure optimal maternal and fetal outcomes.
Examining the Maximum Oxytocin Dose
Researchers conducted a secondary analysis of the Maternal-Fetal Medicine Units Network Assessment of Perinatal Excellence study, analyzing 5,201 individuals who underwent TOLAC. Consequently, they categorized the maximum oxytocin exposure into three groups: 0 milli-international units/min, 1–20 milli-international units/min, and greater than 20 milli-international units/min. This design permitted a clear comparison of risk across different dosing strategies. Of the cohort, 65.5% received no oxytocin while 2.6% received a dose exceeding 20 milli-international units/min.
The primary outcome studied was uterine rupture. This occurred in 37 cases (0.7%) across the entire TOLAC group. Importantly, the frequency of uterine rupture showed a statistically significant upward trend ($P < 0.001$) as the maximum oxytocin dose increased. The rupture rates were 0.2% for those receiving no oxytocin, 1.6% for the 1–20 milli-international units/min group, and rose to 2.2% in the group receiving doses over 20 milli-international units/min. Therefore, this data strongly suggests a threshold effect where higher doses substantially heighten maternal risk.
In addition to uterine rupture, maximum oxytocin dose was associated with secondary adverse outcomes. Higher doses correlated with a decreased rate of vaginal birth after cesarean (VBAC). Furthermore, greater oxytocin exposure was also linked to an increased risk of blood transfusion and intensive care unit (ICU) admission for the patient. Consequently, the researchers conclude that clinicians should use oxytocin with great caution during TOLAC, especially when considering higher-dose protocols.
Clinical Implications and Guidelines
These findings reinforce earlier research that suggests an upper limit of oxytocin in TOLAC should be considered 20 milli-international units/min to avoid an unacceptably high risk of uterine rupture. For instance, one prior study indicated that maximum oxytocin ranges above 20 milli-international units/min could increase the risk of uterine rupture by four-fold or more. Accordingly, the Federation of Obstetric and Gynaecological Societies of India (FOGSI) Good Clinical Practice Recommendations advise avoiding doses above this 20 mU/min limit.
A crucial consideration is the context of labor. Spontaneous labor carries a lower risk profile. However, induction of labor with oxytocin is associated with a higher risk of uterine rupture compared to spontaneous labor. Providers must carefully weigh the likelihood of a successful VBAC against the absolute risks of uterine rupture and severe maternal morbidity when augmenting or inducing labor in a TOLAC candidate.
Frequently Asked Questions
Q1: What is the main finding regarding maximum oxytocin dose and uterine rupture?
The study found a dose-response relationship, with uterine rupture risk trending significantly upward as the maximum oxytocin dose increased. Specifically, the rupture rate was 2.2% in patients who received more than 20 milli-international units/min of oxytocin, compared to 0.2% for those who received none.
Q2: What is the recommended maximum oxytocin dose during TOLAC?
Though an official global maximum is not universally established, this study and previous research strongly support a cautionary approach. Experts and guidelines, including FOGSI, suggest avoiding maximum oxytocin doses exceeding 20 milli-international units/min during Trial of Labor After Cesarean (TOLAC) due to the substantially increased risk of uterine rupture.
Q3: Did the study look at outcomes other than uterine rupture?
Yes, the study also looked at secondary outcomes. Higher maximum oxytocin doses were associated with a lower rate of successful vaginal birth after cesarean (VBAC) and a greater risk of severe maternal morbidity, specifically blood transfusion and admission to the intensive care unit (ICU).
References
- Bruno AM et al. Maximum Oxytocin Dose and Uterine Rupture During Trial of Labor After Cesarean. Obstet Gynecol. 2025 Dec 01. doi: 10.1097/AOG.0000000000006106. PMID: 41325062.
- Wang R et al. Oxytocin use in trial of labor after cesarean and its relationship with risk of uterine rupture in women with one previous cesarean section: a meta-analysis of observational studies. BMC Pregnancy Childbirth. 2021 Jan 6;21(1):28.
- Cahill AG et al. Maximum oxytocin dose and the risk of uterine rupture in women with prior cesarean delivery. Am J Obstet Gynecol. 2008 Jul;199(1):32.e1-5.
- Federation of Obstetric and Gynaecological Societies of India (FOGSI). Good Clinical Practice Recommendations (GCPR) on Delivery after Previous Cesarean Section.